By Tina Reed
Top provider groups are urging the White House to share critical COVID-19 information with the incoming Biden Administration to prevent any potential lapses in care for patients.
read more
By Tina Reed
When the nation's top infectious disease expert Anthony Fauci was asked on Tuesday whether we'd still be wearing masks at Thanksgiving next year, it seemed like a perfect opening for some good news. Unfortunately, his answer was less satisfying than a can of cranberry sauce.
read more
By Fraiser Kansteiner
CureVac, fresh off a large EU supply deal, is looking to build an integrated vaccine manufacturing network across Europe. It plans to enlist a slate of CDMOs and suppliers across the bloc, with the goal to boost capacity for up to 300 million shot doses in 2021 and upward of 600 million doses in 2022.
read more
By Robert King
The Department of Health and Human Services is pushing the Food and Drug Administration to speed up reviews of lab-developed COVID-19 tests, and is asking the National Cancer Institute for help.
read more
By Angus Liu
As the COVID-19 pandemic fuels a global interest in healthcare, many deep-pocketed investors have diverted their money to the sector. Warren Buffett is among those who have now doubled down on their commitments to the biopharma industry as his Berkshire Hathaway plowed billions of dollars into AbbVie, Bristol Myers Squibb, Merck and Pfizer.
read more
By Robert King
A new AHIP survey found that costs for out-of-network COVID-19 tests have been going up since a July survey.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
The U.K. snapped up 5 million Moderna doses Monday. The FDA postponed its decision on BMS' liso-cel after pandemic delays kept inspectors from reviewing a Lonza facility in Texas. Infectious disease experts aren't feeling confident about prescribing an approved shot, a recent survey showed. Plus, an Ohio senator will take part in J&J's vaccine trial.
read more
